CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 620 enrolled
Drug / intervention
Automated Neuropsychological Assessment Matrixdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00117195
NCT00117195N/ACompleted
CompareCT.gov

Open-Label Validation Study of Neurophysiologic Changes in Individuals With Parkinson's Disease, at Risk for Parkinson's Disease and Healthy Controls

Institute for Neurodegenerative Disorders·observational·Posted Jul 4, 2005·Updated Feb 9, 2012

In Brief

An observational study evaluating Automated Neuropsychological Assessment Matrix for Parkinson's Disease and Parkinsonian Syndrome. Completed, enrolled 620 participants across 1 site.

Detailed Summary

The goal of this study is to investigate neurophysiologic tests that have the potential of serving as screening tools for Parkinson's disease. These neurophysiologic tests will be administered to individuals with Parkinson's disease and parkinsonian syndrome and validated against a healthy control population. Specifically, this study will look at changes in motor function, cognitive function, handwriting, speech, and olfactory function in individuals with Parkinson's disease, individuals at risk for Parkinson's disease and healthy controls.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease, Parkinsonian Syndrome
CountriesUnited States
CollaboratorsMolecular NeuroImaging

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 4, 2005
Enrollment StartMay 1, 2003
Primary CompletionJan 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 21.0 years ago

Interventions

Automated Neuropsychological Assessment Matrixdevice

This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions. In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome.